Loading provider…
Loading provider…
Diagnostic Radiology Physician in Sylmar, CA
NPI: 1346581923Primary Practice Location
LAC/OLIVE VIEW-UCLA MEDICAL CENTER
14445 Olive View Dr, Sylmar, CA
Primary Employer
Olive View - UCLA Medical Center
dhs.lacounty.gov
HQ Phone
Get M.D. Evan's Phone Numberphone_androidMobile
Get M.D. Evan's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2015 - 2026
MI State Medical License
2013 - 2016
CA State Medical License

American Board of Preventive Medicine
Clinical Informatics

American Board of Radiology
Diagnostic Radiology
Stanford University School Of Medicine
med.stanford.edu
BA • Human Biology
2002 - 2006
Keck School of Medicine of USC
keck.usc.edu
Medical School
Until 2012
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Abdominal Radiology
2017 - 2018
University of Southern California/Los Angeles General Medical Center (USC/LA General)
Residency • Radiology-Diagnostic
2015 - 2017
University of Michigan
Residency • Radiology-Diagnostic
2013 - 2015
Huntington Memorial Hospital
Internship • Internal Medicine
2012 - 2013
USC School of Public Policy
Health Administration
2006 - 2008
Authors: Phuong Chi Pham, Nina Park, Kamyar Kalantar-Zadeh, Belinda Waltman, Annika Khine, Arshia Ghaffari, Nina Patel, Thomas Le, Hal Yee, Jane Yang, John Sim, John Sim, Susanne Nicholas, Rajiv Dhamija, Lilly Barba
Journal: Clin J Am Soc Nephrol
Publication Date: 2024-11-25
Use of a covered stent modification to produce a transcatheter valve: laboratory and animal testing.
Authors: Daniel Levi, John Moore
Journal: ASAIO J
Lead Sponsor: Exelixis
Collaborators: Roche-Genentech, Takeda
Intervention / Treatment: DRUG: Enzalutamide, DRUG: Prednisone, DRUG: Atezolizumab, DRUG: Cabozantinib, DRUG: Abiraterone Acetate
Lead Sponsor: Exelixis
Intervention / Treatment: DRUG: cabozantinib, DRUG: atezolizumab